Cargando…

Mifepristone Repurposing in Treatment of High-Grade Gliomas

Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Llaguno-Munive, Monserrat, Vazquez-Lopez, Maria Ines, Jurado, Rafael, Garcia-Lopez, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930566/
https://www.ncbi.nlm.nih.gov/pubmed/33680961
http://dx.doi.org/10.3389/fonc.2021.606907
_version_ 1783660122769195008
author Llaguno-Munive, Monserrat
Vazquez-Lopez, Maria Ines
Jurado, Rafael
Garcia-Lopez, Patricia
author_facet Llaguno-Munive, Monserrat
Vazquez-Lopez, Maria Ines
Jurado, Rafael
Garcia-Lopez, Patricia
author_sort Llaguno-Munive, Monserrat
collection PubMed
description Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 months and a 5-year overall survival of <5%. Although new strategies have been sought to enhance patient response, no significant increase in the global survival of glioma patients has been achieved. The option of developing new drugs implies a long and costly process, making drug repurposing a more practical alternative for improving glioma treatment. In the last few years, researchers seeking more effective cancer therapy have pursued the possibility of using anti-hormonal agents, such as mifepristone. The latter drug, an antagonist for progesterone and glucocorticoid receptors, has several attractive features: anti-tumor activity, low cytotoxicity to healthy cells, and modulation of the chemosensitivity of several cancer cell lines in vitro. Hence, the addition of mifepristone to temozolomide-based glioblastoma chemotherapy may lead to a better patient response. The mechanisms by which mifepristone enhances glioma treatment are not yet known. The current review aims to discuss the potential role of mifepristone as an adjuvant drug for the treatment of high-grade gliomas.
format Online
Article
Text
id pubmed-7930566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79305662021-03-05 Mifepristone Repurposing in Treatment of High-Grade Gliomas Llaguno-Munive, Monserrat Vazquez-Lopez, Maria Ines Jurado, Rafael Garcia-Lopez, Patricia Front Oncol Oncology Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 months and a 5-year overall survival of <5%. Although new strategies have been sought to enhance patient response, no significant increase in the global survival of glioma patients has been achieved. The option of developing new drugs implies a long and costly process, making drug repurposing a more practical alternative for improving glioma treatment. In the last few years, researchers seeking more effective cancer therapy have pursued the possibility of using anti-hormonal agents, such as mifepristone. The latter drug, an antagonist for progesterone and glucocorticoid receptors, has several attractive features: anti-tumor activity, low cytotoxicity to healthy cells, and modulation of the chemosensitivity of several cancer cell lines in vitro. Hence, the addition of mifepristone to temozolomide-based glioblastoma chemotherapy may lead to a better patient response. The mechanisms by which mifepristone enhances glioma treatment are not yet known. The current review aims to discuss the potential role of mifepristone as an adjuvant drug for the treatment of high-grade gliomas. Frontiers Media S.A. 2021-02-18 /pmc/articles/PMC7930566/ /pubmed/33680961 http://dx.doi.org/10.3389/fonc.2021.606907 Text en Copyright © 2021 Llaguno-Munive, Vazquez-Lopez, Jurado and Garcia-Lopez http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Llaguno-Munive, Monserrat
Vazquez-Lopez, Maria Ines
Jurado, Rafael
Garcia-Lopez, Patricia
Mifepristone Repurposing in Treatment of High-Grade Gliomas
title Mifepristone Repurposing in Treatment of High-Grade Gliomas
title_full Mifepristone Repurposing in Treatment of High-Grade Gliomas
title_fullStr Mifepristone Repurposing in Treatment of High-Grade Gliomas
title_full_unstemmed Mifepristone Repurposing in Treatment of High-Grade Gliomas
title_short Mifepristone Repurposing in Treatment of High-Grade Gliomas
title_sort mifepristone repurposing in treatment of high-grade gliomas
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930566/
https://www.ncbi.nlm.nih.gov/pubmed/33680961
http://dx.doi.org/10.3389/fonc.2021.606907
work_keys_str_mv AT llagunomunivemonserrat mifepristonerepurposingintreatmentofhighgradegliomas
AT vazquezlopezmariaines mifepristonerepurposingintreatmentofhighgradegliomas
AT juradorafael mifepristonerepurposingintreatmentofhighgradegliomas
AT garcialopezpatricia mifepristonerepurposingintreatmentofhighgradegliomas